ArticleScientific reports2015
Inhibition of neuraminidase by Ganoderma triterpenoids and implications for neuraminidase inhibitor design.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- The antimicrobial potential of Fomitopsis Pinicola across multiple applications.Folia microbiologica · 2026Review
- Mannosylated chitosan-PLGA delivers Ganoderma lucidum triterpenes for oral immunoprotection against H9N2 in broilers.Poultry science · 2026Article
- Ganoderma lucidum spore powder enhances IFN-α-mediated antiviral capacity of COVID-19 vaccine boosters revealed by single-cell multi-omics sequencing.Journal of advanced research · 2026Article
- The Extract of the Endophytic FungusInternational journal of molecular sciences · 2026Article
- Selected strains of the Ganoderma lucidum complex from Finnish forests have excellent broadly acting antiviral properties.Scientific reports · 2025Article
- Exploring the health benefits ofFrontiers in cellular and infection microbiology · 2025Review
- Improvement ofMolecules (Basel, Switzerland) · 2024Article
- Review
- A potential Chinese medicine monomer against influenza A virus and influenza B virus: isoquercitrin.Chinese medicine · 2023Article
- Therapeutic Potential of Bioactive Compounds from Edible Mushrooms to Attenuate SARS-CoV-2 Infection and Some Complications of Coronavirus Disease (COVID-19).Journal of fungi (Basel, Switzerland) · 2023Review
- Pathway analysis of host responses to dengue virus serotype 2 infection and inhibition of viral envelope protein by naringenin fromJournal of biosciences · 2023Article
- Lucidenic acid A inhibits the binding of hACE2 receptor with spike protein to prevent SARS-CoV-2 invasion.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2022Article
- Production Ganoderma lucidum extract nanoparticles by expansion of supercritical fluid solution and evaluation of the antioxidant ability.Scientific reports · 2022Article
- Nutritional Profile and Health Benefits ofFoods (Basel, Switzerland) · 2022Review
- Review
- Anti-viral triterpenes: a review.Phytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2022Review
- A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19.Pharmaceutics · 2021Review
- Discovery and Characterization of the Biflavones FromFrontiers in pharmacology · 2021Article
- Article
- Discovery of Ganoderma lucidum triterpenoids as potential inhibitors against Dengue virus NS2B-NS3 protease.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuraminidase (NA) inhibitors are the dominant antiviral drugs for treating influenza in the clinic. Increasing prevalence of drug resistance makes the discovery of new NA inhibitors a high priority. Thirty-one triterpenoids from the medicinal mushroom Ganoderma lingzhi were analyzed in an in vitro NA inhibition assay, leading to the discovery of ganoderic acid T-Q and TR as two inhibitors of H5N1 and H1N1 NAs. Structure-activity relationship studies revealed that the corresponding triterpenoid structure is a potential scaffold for the design of NA inhibitors. Using these triterpenoids as probes we found, through further in silico docking and interaction analysis, that interactions with the amino-acid residues Arg292 and/or Glu119 of NA are critical for the inhibition of H5N1 and H1N1. These findings should prove valuable for the design and development of NA inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.